García Rodríguez M C, López Granados E, Cambronero Martínez R, Ferreira Cerdán A, Fontán Casariego G
Unidad de Inmunología, Hospital Universitario la Paz.
Allergol Immunopathol (Madr). 2001 May-Jun;29(3):107-13. doi: 10.1016/s0301-0546(01)79028-3.
Knowledge of the molecular defects responsible for some primary immunodeficiency diseases (PIDs) offers undoubted advantages in establishing a reliable diagnosis. Such knowledge would allow us not only to establish a prognosis but also to instigate the most appropriate therapy. After molecular diagnosis, some patients could benefit from gene therapy. However, apart from the diagnosis of the disease, molecular biological techniques also enable more reliable identification of carriers and, when suggested by the family history and when the familial defect is already known, prenatal diagnosis will also be possible, thus establishing the earliest possible treatment. Using the single-stranded conformational polymorphism technique followed by direct sequencing, we found 22 different mutations in 22 patients from unrelated families and with a phenotype compatible with x-linked agammaglobulinemia. Fourteen of these are new, previously undescribed mutations and the remaining eight are already included in the data base (http://www.uta.fi/imt/bioinfo/Btkbase). Analysis of the female carrier was performed in all the mothers and the mutation was de novo in only one patient. Study of the BtK gene enabled differential diagnosis with common variable immunodeficiency disease in some patients who showed absent or very low lymphocyte B counts as well as forms of autosomal recessive agammaglobulinemia. Using the same techniques, we were able to identify mutations in the CD40 ligand gene in three families in which one of the members had clinical and biological phenotype compatible with X-linked hyper-IgM. Molecular diagnosis was very useful in identifying carriers in these families as well as in making the differential diagnosis among patients with common variable immunodeficiency disease. Purely on this were we able to provide appropriate genetic counseling.
了解导致某些原发性免疫缺陷病(PID)的分子缺陷,在确立可靠诊断方面具有毋庸置疑的优势。此类知识不仅能让我们做出预后判断,还能促使我们采取最恰当的治疗方法。分子诊断之后,部分患者可从基因治疗中获益。然而,除了疾病诊断,分子生物学技术还能更可靠地识别携带者,并且在家族病史提示且家族缺陷已知的情况下,也能够进行产前诊断,从而尽早开展治疗。通过单链构象多态性技术并结合直接测序,我们在来自非相关家庭且表型与X连锁无丙种球蛋白血症相符的22例患者中发现了22种不同突变。其中14种是新的、先前未描述的突变,其余8种已包含在数据库中(http://www.uta.fi/imt/bioinfo/Btkbase)。对所有母亲进行了女性携带者分析,仅1例患者的突变是新发的。对BtK基因的研究能够在一些淋巴细胞B计数缺失或极低以及常染色体隐性无丙种球蛋白血症形式的患者中与常见变异型免疫缺陷病进行鉴别诊断。运用相同技术,我们在3个家族中鉴定出了CD40配体基因中的突变,这些家族中有一名成员具有与X连锁高IgM血症相符的临床和生物学表型。分子诊断在识别这些家族中的携带者以及对常见变异型免疫缺陷病患者进行鉴别诊断方面非常有用。纯粹基于此,我们能够提供恰当的遗传咨询。